DeepMed Research

ROCKEFELLER UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Biomarkers In Hidradenitis Suppurativa Participants Receiving Brodalumab

Early Phase 1

Completed

Conditions: Hidradenitis Suppurativa

Interventions: Drug: Brodalumab

First Posted Date: 2019-05-23

Last Posted Date: 2020-06-04

Lead Sponsor: Rockefeller University

Target Recruit Count: 10

Registration Number: NCT03960268

Locations: 🇺🇸
Rockefeller Unviersity, New York, New York, United States

First-in-human Study of 10-1074-LS Alone and in Combination With 3BNC117-LS

Phase 1

Completed

Conditions: Human Immunodeficiency Virus

Interventions: Drug: 10-1074-LS
Drug: 3BNC117-LS

First Posted Date: 2018-06-13

Last Posted Date: 2021-08-04

Lead Sponsor: Rockefeller University

Target Recruit Count: 77

Registration Number: NCT03554408

Locations: 🇺🇸
The Rockefeller University, New York, New York, United States

3BNC117 and 10-1074 in ART-treated Individuals

Phase 1

Completed

Conditions: Human Immunodeficiency Virus

Interventions: Drug: 3BNC117
Drug: 10-1074
Other: Analytical treatment interruption

First Posted Date: 2018-05-16

Last Posted Date: 2022-02-15

Lead Sponsor: Rockefeller University

Target Recruit Count: 26

Registration Number: NCT03526848

Locations: 🇺🇸
The Rockefeller University, New York, New York, United States
🇺🇸
Ragon Institute of MGH, MIT, and Harvard, Boston, Massachusetts, United States

Weight Loss Using a Feedback Device in Obese People With the Metabolic Syndrome

Not Applicable

Withdrawn

Conditions: Pre-Diabetes
Weight Loss
Obesity
Metabolic Syndrome

Interventions: Device: VA MOVE! Coach app
Behavioral: Standard of Care for weight loss.
Behavioral: Telephone Coaching

First Posted Date: 2018-04-09

Last Posted Date: 2018-10-24

Lead Sponsor: Rockefeller University

Registration Number: NCT03491930

Locations: 🇺🇸
Rockefeller University, New York, New York, United States

Yellow Fever Immune Response at Single Cell Resolution

Completed

Conditions: Healthy

Interventions: Drug: Yellow Fever Vaccine

First Posted Date: 2018-03-08

Last Posted Date: 2019-11-08

Lead Sponsor: Rockefeller University

Target Recruit Count: 6

Registration Number: NCT03458780

Locations: 🇺🇸
The Rockefeller University, New York, New York, United States

Effects of Dietary Fructose on Gut Microbiota and Fecal Metabolites in Obese Men and Postmenopausal Women: A Pilot Study

Not Applicable

Completed

Conditions: Obesity
Non-Alcoholic Fatty Liver Disease

Interventions: Other: Fructose Solution (75 Grams)
Other: Glucose Solution (75 grams)

First Posted Date: 2017-11-13

Last Posted Date: 2021-03-26

Lead Sponsor: Rockefeller University

Target Recruit Count: 13

Registration Number: NCT03339245

Locations: 🇺🇸
The Rockefeller University, New York, New York, United States

3BNC117-LS First-in-Human Phase 1 Study

Phase 1

Completed

Conditions: Human Immunodeficiency Virus

Interventions: Drug: 3BNC117-LS
Drug: Placebo

First Posted Date: 2017-08-18

Last Posted Date: 2021-02-03

Lead Sponsor: Rockefeller University

Target Recruit Count: 43

Registration Number: NCT03254277

Locations: 🇺🇸
The Rockefeller University, New York, New York, United States

Impact of Narrowband UVB Phototherapy on Systemic Inflammation in Patients With Atopic Dermatitis

Not Applicable

Completed

Conditions: Atopic Dermatitis

Interventions: Other: Narrow band UVB treatment (NB-UVB)

First Posted Date: 2017-03-20

Last Posted Date: 2020-02-26

Lead Sponsor: Rockefeller University

Target Recruit Count: 6

Registration Number: NCT03083730

Locations: 🇺🇸
The Rockefeller University, New York, New York, United States

Romidepsin Plus 3BNC117 Phase 2a Study

Phase 2

Completed

Conditions: Human Immunodeficiency Virus (HIV)

Interventions: Drug: Romidepsin
Drug: 3BNC117

First Posted Date: 2016-07-29

Last Posted Date: 2022-07-14

Lead Sponsor: Rockefeller University

Target Recruit Count: 48

Registration Number: NCT02850016

Locations: 🇺🇸
The Rockefeller University, New York, New York, United States
🇩🇰
Aarhus University Hospital, Aarhus, Denmark
🇩🇪
University of Cologne, Cologne, Germany

3BNC117 and 10-1074 in HIV-infected Individuals

Phase 1

Completed

Conditions: Human Immunodeficiency Virus (HIV)

Interventions: Drug: 3BNC117
Drug: 10-1074
Drug: Placebo
Other: Analytical treatment interruption

First Posted Date: 2016-07-07

Last Posted Date: 2018-08-21

Lead Sponsor: Rockefeller University

Target Recruit Count: 34

Registration Number: NCT02825797

Locations: 🇩🇪
University Hospital of Cologne, Cologne, Germany
🇺🇸
The Rockefeller University, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy